Merck extends research agreement for NASH drug candidate

By Maggie Lynch contact

- Last updated on GMT


Related tags: Merck, Merck & co, MSD, drug candidate, Research, Collaboration

Merck exercises its option to extend research phase with NGM for an additional two-year period, moving the collaboration end date to March 2022.

The collaboration between Merck, known as MSD outside of North America, and NGM Biopharmaceuticals began in February 2015. The two companies entered an agreement to focus on discovering, developing, and commercializing biologic therapeutics.

Per the original agreement, Merck had the option to extend the initial five-year research and early development phase of the collaboration for an additional two-year period. Merck has exercised its option to extend.

During the two-year extension period, Merck will continue to fund NGM’s R&D efforts. However, Merck will not pay the $20m (€17.6m) extension fee to NGM but instead will make additional payments totaling $20m in support of NGM’s R&D activities during 2021 and 2022.

In January 2019, Merck exercised its option to license NGM313, now known as MK-3655, an investigational monoclonal antibody (mAb) agonist discovered by NGM for the treatment of nonalcoholic steatohepatitis (NASH).

Merck will advance MK-3655 into a Phase IIb study to evaluate the effect of the mAb on liver histology and glucose control NASH patients with or without diabetes.

Terminates license to obesity drug candidate

As part of the original agreement, Merck received an exclusive license to NGM’s growth differentiation factor 15 (GDF15) analogs. At the time of the extension, Merck announced that it will terminate its license to NGM’s GDF15 receptor agonist program developed for the treatment of obesity.

The termination of this license occurred after preliminary data from a study of NGM386, a GDF15 agonist receptor, did not result in body weight loss relative to placebo.

Upon license termination, NGM will gain exclusive license to the GDF15 receptor agonist program, including further development and commercialization of potential products.

Merck has an additional option it can exercise in 2021 to extend the research phase for a further two years.

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us


View more